Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma
| Status: | Completed |
|---|---|
| Conditions: | Asthma |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 12/14/2017 |
| Start Date: | December 9, 2008 |
| End Date: | July 25, 2010 |
A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Evaluate the Efficacy and Safety of Intravenous GSK679586 in Patients With Severe Asthma
Treatment, Randomised, Double Blind, Parallel Assignment, Safety/efficacy Study
A Multi-Centre, Multi-country, Randomized, Double-Blind (Subject, Investigator),
Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous
GSK679586 in Patients with Severe Asthma
Placebo-Controlled, Repeat-Dose study to evaluate the Efficacy and Safety of Intravenous
GSK679586 in Patients with Severe Asthma
Inclusion Criteria:
- history of asthma for ≥ 6 months
- taking inhaled corticosteroids
- non-smoking
- Baseline (pre-bronchodilator) FEV1 35-80% predicted at screening.
- Reversible airways disease as indicated by an increase of FEV1 ≥12% from baseline
after nebulised salbutamol or albuterol.
- symptomatic according to the ACQ-7
Exclusion Criteria:
- Unstable severe asthma
- Recent respiratory illness
- Presence of other respiratory disease or chronic pulmonary condition other than asthma
- Treatment with omalizumab within 4 months of study
- Recent gastrointestinal or respiratory parasitic infestation
- History of severe allergy to food or drugs
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials